Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
Rhea-AI Summary
Lexeo Therapeutics (Nasdaq: LXEO) will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 10:00 a.m. ET in Miami, FL.
The presentation will be webcast live via the company's Investors & News & Events page, with a replay available on the Lexeo website after the session.
Positive
- None.
Negative
- None.
News Market Reaction – LXEO
In the Mar 3 session, LXEO declined 0.84%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Investor conferences | Neutral | -5.2% | Announcement of management participation in two February 2026 investor conferences. |
| Jan 27 | Leadership & partnership | Positive | +0.4% | Senior leadership appointments and update to strategic cardiac RNA partnership. |
| Jan 12 | Clinical data update | Positive | -23.0% | Positive interim Phase I/II HEROIC-PKP2 data for LX2020 in cardiomyopathy. |
| Jan 08 | Research collaboration | Positive | -5.5% | Collaboration with Johnson & Johnson on targeted cardiac AAV gene delivery. |
| Dec 22 | Conference presentation | Neutral | +2.7% | Planned CEO presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive and partnership/clinical news often saw negative next-day moves, while management/strategy updates had the only clearly positive reaction.
Over the last few months, Lexeo’s news flow included multiple conferences, strategic updates, and clinical data. A Dec 22, 2025 J.P. Morgan conference presentation and a Feb 5, 2026 investor conference announcement bracketed more material items, such as a Jan 8, 2026 research collaboration with Johnson & Johnson and Jan 12, 2026 positive interim Phase I/II data for LX2020. Leadership and partnership updates on Jan 27, 2026 drew the only clearly positive price reaction, while clinical and collaboration news saw selling pressure afterward.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 10:00 a.m. ET in Miami, FL.
The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Media Response:
Media@lexeotx.com
Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com
